Literature DB >> 8763853

The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1.

R B Tishler1, D M Lamppu.   

Abstract

The combination of the microtubule active drug taxol with radiation has shown promise for use in combined modality therapy. Recent studies have demonstrated that radiation and a wide range of chemotherapy agents, including microtubule active drugs, induce p53. In certain circumstances, the induction of p53 has been shown to be an important parameter in the response of a tumour to cytotoxic treatment. We examined the induction of p53 and its downstream target, p21WAF1/CIP1, by the microtubule active agents taxol and vinblastine with radiation. An increase in induction of both p53 and p21 WAF1/CIP1 was demonstrated when radiation was added to either taxol or vinblastine treatment. These results, in conjunction with data on taxol and vinblastine induction of p21WAF1/CIP1, suggest a rationale for the combination therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763853      PMCID: PMC2150005     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  26 in total

1.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

Authors:  M Fritsche; C Haessler; G Brandner
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

4.  Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53.

Authors:  R B Tishler; D M Lamppu; S Park; B D Price
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

5.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.

Authors:  G P Zambetti; J Bargonetti; K Walker; C Prives; A J Levine
Journal:  Genes Dev       Date:  1992-07       Impact factor: 11.361

6.  Taxol sensitizes human astrocytoma cells to radiation.

Authors:  R B Tishler; C R Geard; E J Hall; P B Schiff
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

7.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  Taxol: a novel radiation sensitizer.

Authors:  R B Tishler; P B Schiff; C R Geard; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

10.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

View more
  3 in total

Review 1.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.

Authors:  W Roth; B Wagenknecht; C Grimmel; J Dichgans; M Weller
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

3.  Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.

Authors:  K Sugiyama; M Shimizu; T Akiyama; H Ishida; M Okabe; T Tamaoki; S Akinaga
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.